Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study / Bersanelli, M.; Buti, S.; Banna, G. L.; Giorgi, U. D.; Cortellini, A.; Rebuzzi, S. E.; Tiseo, M.; Fornarini, G.; Mazzoni, F.; Panni, S.; Tursi, M. D.; Marino, P. D.; Rossetti, S.; Rossi, E.; Tomao, S.; Luca, E. D.; Soraru, M.; Mucciarini, C.; Atzori, F.; Torre, L. L.; Vitale, M. G.; Martelli, V.; Sepe, P.; Mollica, V.; Vaccaro, V.; Schinzari, G.; Ficorella, C.; Massari, F.; Maestri, A.; Sabbatini, R.; Sava, T.; Maio, M. D.; Verzoni, E.; Procopio, G.; Giannarelli, D.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 12:2(2020), pp. 151-159. [10.2217/imt-2019-0180]

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

Bersanelli M.;Buti S.;Tiseo M.;
2020

Abstract

Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study / Bersanelli, M.; Buti, S.; Banna, G. L.; Giorgi, U. D.; Cortellini, A.; Rebuzzi, S. E.; Tiseo, M.; Fornarini, G.; Mazzoni, F.; Panni, S.; Tursi, M. D.; Marino, P. D.; Rossetti, S.; Rossi, E.; Tomao, S.; Luca, E. D.; Soraru, M.; Mucciarini, C.; Atzori, F.; Torre, L. L.; Vitale, M. G.; Martelli, V.; Sepe, P.; Mollica, V.; Vaccaro, V.; Schinzari, G.; Ficorella, C.; Massari, F.; Maestri, A.; Sabbatini, R.; Sava, T.; Maio, M. D.; Verzoni, E.; Procopio, G.; Giannarelli, D.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 12:2(2020), pp. 151-159. [10.2217/imt-2019-0180]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2881534
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact